Full Year 2020 Performance Highlights
- Consolidated gross sales across all locations for the twelve months ended
December 31, 2020 totaled a Company record$40.6 million , representing year-over-year growth of 23% compared to the twelve months endedDecember 31, 2019 . - Total prescriptions for the twelve months ended
December 31, 2020 totaled 530,700, representing year-over-year growth of 16% compared to the twelve months endedDecember 31, 2019 . - 340B revenue was
$2.8 million , representing year-over-year growth of 300% compared to the twelve months endedDecember 31, 2019 . - Revenues from COVID-19 Rapid Testing totaled approximately
$600,000 during 2020 with over 5000 tested.
- Consolidated gross sales for the month of
December 2020 totaled$3.5 million , representing 9% year-over-year growth (compared toDecember 2019 ), and 3% sequential monthly growth (compared toNovember 2020 ). - Total prescriptions for the month of
December 2020 totaled 46,200, representing 3% year-over-year growth (compared toDecember 2019 ), and 8.5% sequential monthly growth (compared toNovember 2020 ). - 340B revenue was approximately
$230,000 for the month ofDecember 2020 , representing 109% year-over-year growth (compared toDecember 2019 ). - Revenues from COVID-19 Rapid Testing totaled a record
$345,000 for the month ofDecember 2020 , representing 115% sequential monthly growth (compared toNovember 2020 ).
In response to a challenging 2020 context, the Company was able to respond with flexibility and strong execution, capitalizing on Progressive Care’s built-in competitive advantages, including its established delivery infrastructure, to drive a seamless transition into a pandemic-ready operational vision. The Company’s strong results owe in part to its ability to shift in stride to a model centered on contactless prescription delivery, a range of digital solutions, and an overall experience for providers and customers that met the needs of its surrounding communities during an uncertain and unpredictable period.
The Company sees its December performance as particularly important given that it closed the year with one of its strongest months, suggesting both momentum and growing resilience.
For more information about
https://www.facebook.com/ProgressiveCareUS/
https://twitter.com/ProgressCareUS
PharmCoRx
https://www.pharmcorx.com/get-tested-now
https://www.facebook.com/pharmcorx/
https://twitter.com/PharmCoRx
ClearMetrX
https://www.clearmetrx.com/
https://www.facebook.com/clearmetrx/
About
Cautionary Disclosure Regarding Forward-Looking Statements
Forward-Looking Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to
Public Relations Contact:
carlosr@pharmcorx.com
Source:
2021 GlobeNewswire, Inc., source